BOSTON & WEST HAVEN, Conn.--(BUSINESS WIRE)--Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Debanjan Ray, MBA, to its board of directors. Mr. Ray currently serves as President and Chief Executive Officer of Synthekine, and he has served in leadership roles for multiple biotechnology companies.
Normunity Appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer